MedPath

Manuka Honey Nasal Rinse Study

Not Applicable
Withdrawn
Conditions
Rhinosinusitis
Registration Number
NCT02097576
Lead Sponsor
University of Florida
Brief Summary

The purpose of this study is to evaluate whether high-volume nasal rinses with a manuka honey/saline mixture will improve symptom scores, nasal endoscopic findings and CT scan findings compared to nasal saline rinse without manuka honey in patients with chronic rhinosinusitis.

Manuka honey is a honey made from bees that drink the nectar from tea (manuka) trees in New Zealand. It has been shown to have antibacterial activity against common bacteria that cause chronic sinusitis.

Detailed Description

If the subject chooses to participate in the study, the subject will be asked to fill out a symptom questionnaire at the beginning of the study and at each follow-up visit. The subject will be randomly assigned (much like the flip of a coin) to one of two treatment arms in addition to the prescribed medical treatments: 1) nasal rinses twice daily with a saline solution (standard therapy) or 2) nasal rinses with a saline solution mixed with manuka honey (the experimental therapy.) Subjects in the manuka honey/saline rinse arm will perform the experimental rinses twice daily for one month, and then will continue with saline rinses twice daily, with manuka honey added to the rinses only as needed. Nasal rinsing of some kind will be continued through the entire study period.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Chronic Rhinosinusitis
  • Nasal Polyposis stages 1-3
Exclusion Criteria
  • Nasal Polyposis stage 4-5
  • Cystic Fibrosis
  • Immunocompromised patients
  • Allergy to bees or honey

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in SNOT-22 Symptomatic Scores at 6 monthsChange from baseline at 6 months

There are 22 questions, each scored 0 - 5. Possible scores are 0 - 110. The best score is 0, the worst score is 110.

Change in SNOT-22 Symptomatic Scores at 3 monthsChange from baseline at 3 months

There are 22 questions, each scored 0 - 5. Possible scores are 0 - 110. The best score is 0, the worst score is 110.

Change in SNOT-22 Symptomatic Scores at 1 monthChange from baseline at 1 month

There are 22 questions, each scored 0 - 5. Possible scores are 0 - 110. The best score is 0, the worst score is 110.

Secondary Outcome Measures
NameTimeMethod
Change in Endoscopic Scores of CRS severity in the different treatment arms at 3 monthsChange in baseline at 3 months
Change in Endoscopic Scores of CRS severity in the different treatment arms at 1 monthChange in baseline at 1 month
Change in Endoscopic Scores of CRS severity in the different treatment arms at 6 monthsChange in baseline at 6 months
Change in Radiologic Scores of CRS severity in the different treatment arms at 3 monthsChange in baseline at 3 months

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.